In this research, we found that TrkA was especially highly expressed in glioma tissues, which might explain the preferential activity of GA-amide against tumor cells and indicate that GA-amide may be more effective in patients with high TrkA expression. This evidence concerns the gene NTRK1 and central nervous system cancer.